TRANSCENTA-B (06628) Receives First Installment Payment for Sale of CDMO Assets

TRANSCENTA-B (06628) Announces First Installment Payment Received for Sale of CDMO Assets TRANSCENTA-B (06628) issued an announcement regarding, among other things, the sale of CDMO assets to the buyer (a wholly-owned subsidiary of WuXi Biologics) for a total consideration of RMB 190 million. As of the date of this announcement, the Group has received from the buyer the first installment payment of the consideration on a net-of-tax basis, amounting to RMB 95 million, in accordance with the terms of the asset purchase agreement. The proceeds received will be used to supplement the Group's general working capital and to develop the Group's product pipeline. As a result of the sale of CDMO assets, the Group's labor costs and operating expenses are expected to decrease in 2027 compared to 2026. The handover of the CDMO assets is in progress, and the Company expects to receive additional proceeds before the end of 2026, subject to the relevant terms and conditions of the asset purchase agreement.